Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SELL | P14151 | 1/20 | 0.64 |
| ▸ | SELP | P16109 | 1/20 | 0.64 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | SHBG | P04278 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | MYC | P01106 | 1/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | PDE4A | P27815 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30463104 | 1.00 | SELL (0.64) | SELLSELPGRM1ALDH1A1HSD17B10 | |
| Ethylbenzene SCHEMBL10723361 | 0.84 | MEN1 (0.50) | SELLSELPGRM1ALDH1A1HSD17B10 | |
| SCHEMBL30443442 | 0.84 | SELL (0.54) | SELLSELPALDH1A1HSD17B10KDM4E | |
| SCHEMBL317575 | 0.84 | SELL (0.54) | SELLSELPALDH1A1HSD17B10KDM4E | |
| SCHEMBL1758260 | 0.84 | KMT2A (0.51) | SELLSELPALDH1A1HSD17B10KDM4E | |
| SCHEMBL1669747 | 0.83 | KMT2A (0.65) | ALDH1A1HSD17B10KDM4EHPGDMEN1 | |
| SCHEMBL334851 | 0.82 | MEN1 (0.50) | SELLSELPALDH1A1HSD17B10KDM4E | |
| SCHEMBL317576 | 0.82 | ALDH1A1 (0.57) | SELLSELPGRM1ALDH1A1HSD17B10 | |
| SCHEMBL30149140 | 0.82 | ALDH1A1 (0.57) | SELLSELPGRM1ALDH1A1HSD17B10 | |
| SCHEMBL29457560 | 0.82 | MEN1 (0.50) | SELLSELPALDH1A1HSD17B10KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 172 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1300488-B1 | Plating path and method for depositing a metal layer on a substrate | ROHM & HAAS ELECT MAT (US) | 2017-09-27 | — | — | EP | claimed |
| US-8481519-B2 | Isolation of atraric acid, synthesis of atraric acid derivatives, and use of atraric acid and the derivatives thereof for the treatment of benign prostatic hyperplasia, prostate carcinoma and spinobulbar muscular atrophy | LTS LOHMANN THERAPIE-SYSTEME AG (DE) | 2013-07-09 | — | — | US | claimed |
| EP-1850857-B1 | ISOLATION OF ATRARIC ACID, SYNTHESIS OF ATRARIC ACID DERIVATIVES, AND USE OF ATRARIC ACID AND THE DERIVATIVES THEREOF FOR THE TREATMENT OF PROSTATE CARCINOMA. | LOHMANN THERAPIE SYST LTS (DE) | 2013-05-22 | — | — | EP | claimed |
| US-20090143466-A1 | Isolation of Atraric Acid, Synthesis of Atraric Acid Derivatives, and Use of Atraric Acid and the Derivatives Thereof for the Treatment of Benign Prostatic Hyperplasia, Prostate Carcinoma and Spinobulbar Muscular Atrophy | LTS LOHMANN THERAPIE-SYSTEME AG (DE) | 2009-06-04 | — | — | US | claimed |
| EP-1850857-A2 | ISOLATION OF ATRARIC ACID, SYNTHESIS OF ATRARIC ACID DERIVATIVES, AND USE OF ATRARIC ACID AND THE DERIVATIVES THEREOF FOR THE TREATMENT OF BENIGN PROSTATE HYPERPLASIA, PROSTATE CARCINOMA, AND SPINOBULBAR MUSCULAR ATROPHY | LTS LOHMANN Therapie-Systeme AG (DE) | 2007-11-07 | — | — | EP | claimed |
| WO-2006081997-A2 | ISOLATION OF ATRARIC ACID, SYNTHESIS OF ATRARIC ACID DERIVATIVES, AND USE OF ATRARIC ACID AND THE DERIVATIVES THEREOF FOR THE TREATMENT OF BENIGN PROSTATE HYPERPLASIA, PROSTATE CARCINOMA, AND SPINOBULBAR MUSCULAR ATROPHY | LTS LOHMANN THERAPIE-SYSTEMS AG (DE) | 2006-08-10 | — | — | WO | claimed |
| US-20050139118-A1 | Brightener degradation inhibitor compound in copper plating bath | SHIPLEY COMPANY, L.L.C. (US) | 2005-06-30 | — | — | US | claimed |
| US-6911068-B2 | Plating bath and method for depositing a metal layer on a substrate | SHIPLEY COMPANY, L.L.C. (US) | 2005-06-28 | — | — | US | claimed |
| US-20040206631-A1 | Plating bath and method for depositing a metal layer on a substrate | SHIPLEY COMPANY, L.L.C. | 2004-10-21 | — | — | US | claimed |
| EP-1300488-A2 | Plating path and method for depositing a metal layer on a substrate | Shipley Co. L.L.C. (US) | 2003-04-09 | — | — | EP | claimed |
| WO-2025202488-A1 | ENHANCER OF NUCLEIC ACID AMPLIFICATION | ROCHE DIAGNOSTICS GMBH (DE) | 2025-10-02 | — | — | WO | disclosed |
| US-20250228811-A1 | Triester Compounds And Methods Of Use Thereof | LIFEMINE THERAPEUTICS, INC. | 2025-07-17 | — | — | US | disclosed |
| WO-2025137071-A2 | TRIESTER COMPOUNDS AND METHODS OF USE THEREOF | LIFEMINE THERAPEUTICS, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| US-20250188266-A1 | MODIFIED PHENOLIC RESINS FOR MAKING COMPOSITE PRODUCTS | Bakelite UK Holding Ltd. (GB) | 2025-06-12 | — | — | US | disclosed |
| US-12303970-B2 | Foundry mix including resorcinol | Novis Works, LLC (US) | 2025-05-20 | — | — | US | disclosed |
| US-5064914-A | By transesterification; high melt strength; extrusion, blow molding | GENERAL ELECTRIC COMPANY (US) | 1991-11-12 | — | — | US | disclosed |
| EP-0384350-A1 | Dihydroxy naphthalene derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1990-08-29 | — | — | EP | disclosed |
| EP-0351849-A2 | Resist composition | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1990-01-24 | — | — | EP | disclosed |
| EP-0028063-B1 | PHENOL DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLAXO GROUP LIMITED (GB) | 1984-06-13 | — | — | EP | disclosed |
| EP-0028063-A1 | Phenol derivatives, processes for their preparation and pharmaceutical compositions containing them | GLAXO GROUP LIMITED (GB) | 1981-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12303970-B2 | Foundry mix including resorcinol | PRRC2C, ASH2L, RCOR1 | SELL 891/4885SELP 1923/4885GRM1 743/4885 |
| US-20090143466-A1 | Isolation of Atraric Acid, Synthesis of Atraric Acid Derivatives, and Use of Atraric Acid and the Derivatives Thereof for the Treatment of Benign Prostatic Hyperplasia, Prostate Carcinoma and Spinobulbar Muscular Atrophy | RARB, RARA, AR | SELL 4859/4885SELP 4771/4885GRM1 2105/4885 |
| US-20250228811-A1 | Triester Compounds And Methods Of Use Thereof | CYP46A1, CYP17A1, CYP27A1 | SELL 2288/4885SELP 1928/4885GRM1 3737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.